Rezatapopt and azacitidine for AML or MDS with a specific TP53 mutation
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a new drug, rezatapopt, combined with azacitidine for people with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) that has come back or not responded to treatment. It is only for people whose cancer cells have a specific change in a gene called TP53 (the Y220C mutation). The goal is to see if this combination can help control the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- You must have acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) that has come back after treatment (relapsed) or did not respond to prior treatment (refractory).
- Your cancer cells must have a specific change in the TP53 gene called Y220C. This must be confirmed by a standard lab test, and the change must be present in more than 2% of the cells tested.
- You must be able to take care of yourself and be up and about at least half of the day (ECOG score 0-2).
- Your liver and kidney function must be within certain limits, as determined by blood tests.
- If you could become pregnant, you must have a negative pregnancy test and agree to use effective birth control during the study and for a few months after.
- You cannot have received certain cancer treatments within 14 days before starting the study drugs.
- You cannot have certain active infections (like HIV, hepatitis B or C) or other serious medical conditions that would make the study unsafe.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug (axatilimab) combined with two standard chemotherapy drugs (decitabine and venetoclax) for people with acute myeloid leukemia (AML) that has a TP53 mutation. The goal is to see if this combination helps control the cancer better than current treatments.
This trial tests a combination of drugs for people with AML who, after initial treatment, have very low levels of leukemia still present (called measurable residual disease or MRD). The goal is to wipe out these remaining cells and reduce the chance of the cancer coming back.
This trial tests a new drug called LP-108 combined with azacitidine for people with certain blood cancers like acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), or chronic myelomonocytic leukemia (CMML). It aims to see if the combination is safe and helps shrink or control the cancer.
This trial tests a new drug called RPT1G for adults with acute myeloid leukemia or high-risk myelodysplastic syndromes that have not responded to standard treatments. The goal is to see if the drug is safe and if it shows signs of helping control the disease.
This trial tests a new combination of two drugs (bortezomib and CPX-351) for people newly diagnosed with a specific type of AML that has a TP53 gene change. The goal is to see if this combination is safe and works better than standard treatment.
This trial tests combining two drugs, ropeginterferon alfa-2b and azacitidine, for people with myelodysplastic syndrome or acute myeloid leukemia that has a TP53 gene change. The treatment may help control the cancer, and the study includes people who are newly diagnosed or whose disease has not responded to prior therapy.
Hear when a new Acute Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.